drugset
drugset / Trial / NCT01720303

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

NCT01720303 ↗

Phase 4 Completed 159 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

Timeline

Start
2002-09-19
Primary completion
2003-04-10
Completion
2003-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic — Subcutaneous
Subject Repaglinide Small molecule 2 mg Oral
Subject isophane human insulin Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus